市場調查報告書

乾眼症疾病市場 - 成長,趨勢,及預測(2019年 - 2024年)

Dry Eye Disease Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 892622
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
Back to Top
乾眼症疾病市場 - 成長,趨勢,及預測(2019年 - 2024年) Dry Eye Disease Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年06月01日內容資訊: 英文 115 Pages
簡介

全球乾眼症疾病市場在2018年估算為45億3,922萬美金。該市場在2019年∼2024年間,預測將以5.23%的年複合成長率成長,2024年達到61億7,596萬美元。

本報告提供全球乾眼症疾病市場的相關調查,市場趨勢和機會,成長及阻礙因素,產品、流通管道、各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查的成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
  • 市場阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各產品
    • 人工淚液
    • 抗發炎藥
    • 淚點塞
    • 分泌促進物質
    • 其他
  • 各流通管道
    • 醫院藥局
    • 獨立型藥局及藥妝店
    • 線上藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Allergan PLC
    • Novartis AG
    • 參天製藥株式會社
    • OASIS Medical
    • Bausch Health
    • Sun Pharmaceutical Industries Ltd
    • 大塚製藥株式會社
    • Johnson & Johnson
    • VISUfarma
    • Sentiss Pharma Pvt. Ltd

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64754

Market Overview

The Dry Eye Disease market studied was valued at USD 4,539.22 million in 2018, and is expected to reach USD 6,175.96 million by 2024, with an anticipated CAGR of 5.23%, during the forecast period (2019-2024). Several factors may be associated with the growth of dry eye related diseases, such as aging, a decrease in the supportive hormones, systemic inflammatory diseases, ocular surfaces diseases or surgeries affecting the cholinergic nerves, which stimulate tear secretion.

A significant percentage of the global population (middle age to older age) suffer from dry eye syndrome. It is particularly more common among women than in men. Additionally, working for long hours on computer screens as well as long term contact lens use cause dry eye. In addition, several manufacturers are exploring the alternative drug class or procedure, with improvement in diagnostic tools, to identify and enhance the tear stimulating factors, which drives the importance of dry eye disease correction. Thus, the rise in geriatric population and the technological advancements and promising pipeline products will further help in the market growth.

Scope of the Report

Dry eye disease refers to a disturbance of the lacrimal functional unit, which comprises of the lacrimal glands, ocular surface (cornea, conjunctiva and meibomian glands) and lids, and the sensory and motor nerves that connect them. There are several ocular manifestations for which several dry eye products are used for the treatment of the disease.

Key Market Trends

Corticosteroid Drugs is Expected to Grow with a Decent CAGR in the Anti-Inflammatory Drugs Segment

Corticosteroids are effective anti-inflammatory drugs, widely available, that rapidly relieve the symptoms and signs of moderate and severe dry eye. These drugs are highly useful in short term efficacy and thus prescribed mostly for acute cases of dry eye diseases. However, with the long term usage of these drugs, there are major side effects, such as intraocular pressure elevation and cataract progression. Two of the major companies established in this segment are Bausch Health and Allergan. Often, these companies, as well as doctors, recommend corticosteroid along with antibiotic therapy.

Some of the common interventions include dietary omega-3 essential fatty acids, such as fish oils or flaxseed oil; or the use of lipid-based artificial tears to augment the deficient lipid layer; and/or a short course of a topical ester-based corticosteroid, in order to address the inflammatory component of the dry eye. Over the forecast period, with the severity of disease at the chronic level of the disease, the corticosteroids are most extensively used. Their share is thus considered to be largest, growing at a steady CAGR over the forecast period.

Asia Pacific is expected to grow with High CAGR and Expected to do Same in the Forecast Period

Geographically, the North American region holds a major share, whereas the Asia-Pacific region is estimated to be the fastest growing. Several factors, such as hospital infrastructure, procuring new technology devices for diagnosis of diseases, early market approval of the product, a large number of ophthalmic surgeries, early awareness in the society, drive the market in the North American region. In Asia, a large number of generic production, good distribution of local and international players, and the fast economic growth of the country are factors driving the growth of the studied market.

Competitive Landscape

The Dry Eye Disease market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising geriatric population and high prevalence of diseases, few other smaller players are expected to enter into the market in the coming years. Some of the major players of the market are Allergan PLC, Novartis AG, Santen Pharmaceutical Co. Ltd, OASIS Medical, and Bausch Health are among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Dry Eye Disease
    • 4.2.2 Novel Dry Eye Diagnostic Tools in Offering
    • 4.2.3 Technological Advancements and Promising Pipeline Products
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Specialty Dry Eye Products with Complex Reimbursement Scenario
    • 4.3.2 Alternative Therapies in Offering
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Products
    • 5.1.1 Artificial Tears
    • 5.1.2 Anti-Inflammatory Drugs
      • 5.1.2.1 Cyclosporine
      • 5.1.2.2 Corticosteroid
      • 5.1.2.3 Other Anti-inflammatory Drugs
    • 5.1.3 Punctal Plugs
    • 5.1.4 Secretagogues
    • 5.1.5 Other Products
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Independent Pharmacies and Drug Stores
    • 5.2.3 Online Pharmacies
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan PLC
    • 6.1.2 Novartis AG
    • 6.1.3 Santen Pharmaceutical Co. Ltd
    • 6.1.4 OASIS Medical
    • 6.1.5 Bausch Health
    • 6.1.6 Sun Pharmaceutical Industries Ltd
    • 6.1.7 Otsuka Pharmaceutical Co. Ltd
    • 6.1.8 Johnson & Johnson
    • 6.1.9 VISUfarma
    • 6.1.10 Sentiss Pharma Pvt. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top